Those interested in the lithium sector and investing in lithium stocks are often curious about which countries produce the most of the battery metal,...
The Supreme Court wades back into hot-button issues including gun control, the death penalty and gender-affirming care for minors in the term that begins...
Washington and Massachusetts are stockpiling abortion pills. California is cutting climate deals directly with automakers. Colorado is rushing to protect the right to same-sex...
In this StockCharts TV video, Mary Ellen highlights the continuation rally in AI-related stocks while also reviewing broader market conditions. The move higher in yields...
After Friday’s stellar jobs report—254,000 jobs added in September vs. the Dow Jones forecast of 15,000—stocks and Treasury yields initially reacted with a big...
As a bull market reaches an exhaustion point, market breadth indicators often tend to diverge from the price action of the benchmarks. This “breadth divergence”...
It’s time for a wellness check at CVS Health. Shares of the company are down more than 20% this year as it grapples with higher-than-expected medical...
Geopolitical tension clashed with uplifting jobs data, making for an interesting week on Wall Street. Meanwhile, the crypto market went on a wild ride...
Americans have increasingly soured on the Secret Service following the assassination attempt in July that wounded former president Donald Trump, according to a Gallup...
The S&P/TSX Venture Composite Index (INDEXTSI:JX) gained 35.21 points this week to close at 580.43. Meanwhile, the S&P/TSX Composite Index (INDEXTSI:OSPTX) was up 787.22...
Commodities giant BHP (ASX:BHP,NYSE:BHP,LSE:BHP) announced on Wednesday (September 18) that it will partner with the Meewasin Valley Authority on efforts to conserve the Meewasin...
The US Department of Commerce and US Department of State have announced the inaugural meeting of the International Network of AI Safety Institutes, scheduled...
Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the Company’s Phase 2a clinical trial investigating narmafotinib in the...
Join The Exclusive Subscription Today And Get Premium Articles For Free
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!